在资源有限环境中用床旁数据近似分子脓毒症亚型:乌干达多中心分析
本研究为乌干达两项前瞻性观察性脓毒症队列的二次分析,纳入≥18岁住院脓毒症成人,分别有转录组(n=355)和/或蛋白组(n=495)分子分型数据。评估预设临床及临床-微生物模型对乌干达来源分子亚型的判别与校准。在RESERVE-U-2-TOR中,含人口学与生理变量的临床模型对转录组和蛋白组亚型AUROC分别为0.75(95%CI 0.69–0.81)和0.73(95%CI 0.66–0.80),校准尚可;加快速HIV、疟疾、结核检测未显著改善。在RESERVE-U-1-EBB中判别变异更大(AUROC 0.63–0.75),校准尚可。对高收入国家来源亚型及免疫失调框架表现同样有限。结论:床旁变量仅部分近似分子框架,需可扩展分子标志物平台。
要点
- 在RESERVE-U-2-TOR队列,含人口学与生理变量的临床模型对转录组和蛋白组脓毒症亚型的AUROC分别为0.75(95%CI 0.69–0.81)和0.73(95%CI 0.66–0.80)。
- 加做快速HIV、疟疾和结核检测未对临床模型判别力带来有意义的提升。
- 在RESERVE-U-1-EBB队列,临床模型判别力变异更大,AUROC范围0.63–0.75,校准总体尚可。
- 床旁变量对高收入国家来源的脓毒症亚型及免疫失调框架的判别表现同样有限。
- 结论提示资源有限环境下仅靠床旁数据不能可靠替代分子分型,需可扩展的分子生物标志物平台。
适用人群与场景
- 乌干达Tororo综合医院(RESERVE-U-2-TOR)和Entebbe区域转诊医院(RESERVE-U-1-EBB)收治的≥18岁住院脓毒症成人。
- 纳入者接受了转录组(n=355)和/或蛋白组(n=495)分子分型检测。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 设计:两项前瞻性观察性脓毒症队列的二次分析,在乌干达两家医院进行。
- 人群与样本量:≥18岁住院脓毒症成人,转录组n=355,蛋白组n=495。
- 干预/暴露:评估预设的临床模型和临床-微生物模型,对乌干达来源转录组和蛋白组脓毒症亚型进行判别与校准,次要评估对高收入国家来源亚型及免疫失调框架的表现。
- 主要结果:RESERVE-U-2-TOR中,含人口学与生理变量的临床模型对转录组和蛋白组亚型AUROC分别为0.75(95%CI 0.69–0.81)和0.73(95%CI 0.66–0.80),校准总体可接受;加快速HIV、疟疾、结核检测未显著改善。
- RESERVE-U-1-EBB中判别力变异更大(AUROC 0.63–0.75),校准总体可接受;对高收入国家来源亚型及免疫失调轴表现同样有限。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列的二次分析(非随机对照试验)。
- 局限:为二次分析;两个队列表现不一(AUROC 0.63–0.75);床旁变量仅部分近似分子框架,不能替代分子诊断。
对床旁实践的改变
- 在乌干达等资源有限环境中,不应仅凭床旁临床变量(含或不含快速HIV、疟疾、结核检测)来推断分子脓毒症亚型以指导精准治疗。
- 床旁模型判别力仅中等(AUROC 0.63–0.75),提示需可扩展分子生物标志物平台推进脓毒症精准医学。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Biologically defined sepsis subtypes have been identified in low- and middle-income countries (LMICs), but limited access to molecular diagnostics constrains broader evaluation and implementation in resource-limited settings.
OBJECTIVES: To determine whether bedside-accessible variables could approximate molecular sepsis subtype assignments among Ugandan adults with sepsis.
DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of two prospective observational sepsis cohorts conducted at Tororo General Hospital (Research in the Epidemiology of Severe and Emerging Infections in Uganda-2-Tororo [RESERVE-U-2-TOR]) and Entebbe Regional Referral Hospital (Research in the Epidemiology of Severe and Emerging Infections in Uganda-1-Entebbe [RESERVE-U-1-EBB]), Uganda. Participants were adults 18 years old or older hospitalized with sepsis who underwent transcriptomic (n = 355) and/or proteomic (n = 495) profiling.
MAIN OUTCOMES AND MEASURES: Prespecified clinical and clinico-microbiologic models were evaluated for discrimination and calibration against Uganda-derived transcriptomic and proteomic sepsis subtypes and, secondarily, high-income country (HIC)-derived sepsis subtypes and immune dysregulation frameworks.
RESULTS: In RESERVE-U-2-TOR, clinical models incorporating demographic and physiologic variables showed moderate discrimination for transcriptomic and proteomic subtypes (area under the receiver operating characteristic curve [AUROC], 0.75 [95% CI, 0.69-0.81] and 0.73 [95% CI, 0.66-0.80], respectively), with generally acceptable calibration. Adding rapid HIV, malaria, and tuberculosis test results did not meaningfully improve performance. In RESERVE-U-1-EBB, discrimination was more variable (AUROC range, 0.63-0.75), with generally acceptable calibration. Performance was similarly modest for HIC-derived sepsis subtypes and immune dysregulation axes.
CONCLUSIONS AND RELEVANCE: Bedside-accessible clinical variables, with or without rapid microbiologic testing, only partially approximated molecular sepsis frameworks in Uganda. Scalable molecular biomarker platforms are needed to advance precision medicine for sepsis in LMICs.
参考来源
- Bakamutumaho B, Lutwama JJ, Owor N, et al. Approximating Molecular Sepsis Subtypes Using Bedside Data in Resource-Limited Settings: A Multicenter Analysis From Uganda. Crit Care Explor. 2026. PMID: 42611628. doi:10.1097/CCE.0000000000001463
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。